Bortenat Injection | Bortecad 2mg | Myezom | Velcade - Bortezomib

BORTEZOMIB INJECTION

Bortezomib belongs to anti-cancer medicine, which is available in the form of lyophilized powder. Bortezomib is a first beneficial proteasome inhibitor; proteasome is a cellular structure that breaks the proteins.

INDICATION

Bortezomib is majorly used to treat

1. Multiple myeloma.
2. Mantle cell lymphoma.

DOSAGE AND ADMINISTRATION

Generally, Bortezomib is in lyophilized powder form; which is reconstituted by using 0.9% sodium chloride (NS) Bortezomib should be reconstituted in 3.5ml NS The route of administration is IV bolus Intrathecal not use for administration.

IN ADULTS

MANTLE CELL LYMPHOMA

The usual dose of Bortezomib for untreated mantle cell lymphoma is; 

1.3mg/m2 of Bortezomib administered as IV bolus given as two times weekly by combining with rituximab, cyclophosphamide, doxorubicin, and tablet prednisolone for two weeks (the day I, IV, VIII & XI) followed by 10 day rest period (day II through 21) 

In Relapse stage: 

The recommended dose is 1.3mg/m2 administered as IV bolus or subcutaneous two times for two weeks (day I, IV, VIII & XI) followed by 10-day rest period (day II through 21) The treatment continued for above 8 cycles may be taken for once weekly for 4 weeks (day 1, 8, 15 & 22), followed by 13-day rest (days 23 through 35)

MULTIPLE MYELOMA

In the therapy of previously untreated multiple myeloma: 1.3mg/m2 of dose should be administered as 3 to 5 seconds through IV bolus or subcutaneous by combining with tablet melphalan and prednisolone for nine 6 weeks therapy cycles Cycles 1 over 4, is taken for two times weekly, (day 1, 4, 8, 11, 22, 25, 29 and 32) Cycles 5 over 9, is taken once a week (day 1, 8, 22, and 29)

MOST COMMON SIDE EFFECTS

Black tarry stools Bleeding gums Blood in urine Blurred vision Body aches Burning, crawling, itching, numbness, prickling Chest pain Cough producing mucus, dizziness, faintness, nerve pain, painful urination, pale skin, runny nose, sore throat, stuffy nose, swollen glands, sunken eyes, ulcer, dry mouth, ear congestion, loss of voice.

PRECAUTION AND WARNING

Bortezomib leads so peripheral neuropathy like a burning sensation, hyperesthesia, hypoesthesia, paresthesia, neuropathic pain Manage postural Hypotension by altering the antihypertensive agents, hydration, and administration of mineralocorticoids or sympathomimetics Cardiac toxicity Pulmonary toxicity like Acute Respiratory Distress Syndrome, pneumonitis, interstitial pneumonia, lung infiltration.

Posterior reversible encephalopathy syndrome-stop the Bortezomib therapy Gastrointestinal toxicity-fluid or electrolyte replacements have to take Thrombocytopenia and neutropenia Tumor lysis syndrome Hepatic toxicity Embryo-fetal toxicity.

PREGNANCY AND LACTATION

Bortezomib is not recommended in pregnancy condition, it causes harm to fetus Breastfeeding is not recommended. 

STORAGE

Bortezomib vial should be stored at 20°C to 25°C (68°F to 77°F); excursion between 15°C to 30°C (59°F to 86°F) Keep away from light and heat.

MISSED DOSE

Bortezomib is not a normal medicine used as an anti-cancer drug; it is not to be self-medicated If the patient fails to take the dose of Bortezomib, must consult with a medical oncologist and followed the dosing schedules Do not self-administered Follow the advice given by the physician and do not missed the cycles for the course of therapy.

FOR MORE INFORMATION:

EMAIL:

info@blueberrypharma.com

PHONE:

+91-97890 77748

VISIT US:

Bortezomib ( Bortenat 2mg, Bortenat 3.5mg, Myezom 2mg , Myezom 30.mg )